473254-28-3

Usage

Uses

Used in Pharmaceutical Industry:
2H-Thiopyran-4-methanol, tetrahydro-, 1,1-dioxide is used as a potential pharmaceutical agent due to its heterocyclic structure, which may exhibit biological activity. Its unique chemical properties could be harnessed for the development of new drugs or therapeutic agents.
Used in Organic Synthesis:
2H-Thiopyran-4-methanol, tetrahydro-, 1,1-dioxide serves as a building block in the synthesis of various organic compounds. Its heterocyclic nature and functional groups make it a valuable intermediate in the creation of complex organic molecules for a range of applications.
Further research and testing are necessary to fully understand the properties and potential uses of 2H-Thiopyran-4-methanol, tetrahydro-, 1,1-dioxide, ensuring its safe and effective application in various industries.

Upstream product

• 100277-27-8 (tetrahydro-2H-thiopyran-4-yl)methanol 
• 917807-18-2 methyl tetrahydro-2H-thiopyran-4-carboxylate-1,1-dioxide 
• 128094-82-6 tetrahydro-thiopyran-4-carboxylic acid methyl ester 
• 64096-87-3 1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-carboxylic acid 
• 195503-40-3 tetrahydro-2H-thiopyrane-4-carbonitrile 
• 89489-53-2 tetrahydro-2H-thiopyran-4-carboxylic acid 
• 1072-72-6 Tetrahydrothiopyran-4-one 

Downstream Products

• 928149-12-6 (1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl 4-methylbenzenesulfonate 
• 494210-61-6 1,1-dioxo-hexahydro-1λ⁶-thiopyran-4-carbaldehyde 
• 1010836-46-0 methanesulfonic acid (1,1-dioxo-hexahydro-1-thiopyran-4-yl)methyl ester 
• 1453861-65-8 2-(3-(4-((2'-chloro-4'-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetic acid 
• 1453861-64-7 ethyl 2-(3-(4-((2'-chloro-4'-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate 
• 1453861-40-9 2-(3-(4-((4'-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetic acid 
• 1453861-39-6 ethyl 2-(3-(4-((4'-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methoxy)-2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)phenyl)oxetan-3-yl)acetate 

Relevant academic research and scientific papers

A Chemical Probe for the ATAD2 Bromodomain

ATAD2 is a cancer-associated protein whose bromodomain has been described as among the least druggable of that target class. Starting from a potent lead, permeability and selectivity were improved through a dual approach: 1) using CF2as a sulfone bio-isostere to exploit the unique properties of fluorine, and 2) using 1,3-interactions to control the conformation of a piperidine ring. This resulted in the first reported low-nanomolar, selective and cell permeable chemical probe for ATAD2.

A practical, efficient synthesis of 1,1-dioxo-hexahydro-1#-thiopyran-4- carbaldehyde

A practical, efficient, and scalable procedure for the preparation of l,1-dioxo-hexahydro-1λ6-thiopyran-4-carbaldehyde is reported. Synthesis of this aldehyde was complicated by high aqueous solubility of the product and the intermediates. The isolation and purification of the aldehyde was accomplished by conversion to the crystalline bisulfite adduct.

Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors

ATAD2 is a bromodomain-containing protein whose overexpression is linked to poor outcomes in a number of different cancer types. To date, no potent and selective inhibitors of the bromodomain have been reported. This article describes the structure-based optimization of a series of naphthyridones from micromolar leads with no selectivity over the BET bromodomains to inhibitors with sub-100 nM ATAD2 potency and 100-fold BET selectivity.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

SUBSTITUTED ALKYL CARBOXYLIC ACID DERIVATIVES AS GPR AGONISTS

The present invention relates to substituted alkyl carboxylic acid derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as GPR (G-protein coupled receptor) agonists,

PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS

The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.